Linezolida Hikma

Linezolid, the active ingredient in Linezolida Hikma, is an oxazolidinone presented as an injection for intravenous use. It is employed to treat complicated skin and soft tissue infections, community‑acquired and nosocomial pneumonia, and infections caused by MRSA or VRE in adult patients.

GNH USA supplies Linezolida Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Linezolid is an oxazolidinone antibacterial indicated for several serious bacterial infections. - Complicated skin and soft tissue infections: effective against Gram‑positive pathogens including MRSA. - Community‑acquired pneumonia: provides coverage for susceptible organisms. - Nosocomial pneumonia: used for hospital‑acquired lower respiratory infections. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: treats infections caused by MRSA. - Vancomycin‑resistant Enterococcus (VRE) infections: active against VRE strains.

Linezolid may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Vomiting - Rash - Metallic taste

Serious or Rare Side Effects: - Thrombocytopenia - Anemia - Peripheral neuropathy - Serotonin syndrome - Lactic acidosis - Optic neuropathy

Use of Linezolida Hikma requires careful clinical monitoring. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution and assess liver enzymes regularly. - Serotonergic agents: avoid concomitant use due to risk of serotonin syndrome. - Myelosuppression: perform routine blood‑count monitoring during therapy. - Pregnancy: safety unknown; weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic drugs: risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): increased serotonin syndrome risk. - Rifampin: reduces linezolid plasma concentrations, compromising efficacy. - Carbamazepine and other enzyme‑inducing anticonvulsants: may lower linezolid levels.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR, requiring coagulation monitoring. - Theophylline: linezolid can raise theophylline levels, watch for toxicity. - Nucleoside analogues (e.g., zidovudine): potential additive myelosuppression, monitor blood counts.